Sage Therapeutics, Inc. (Nasdaq: SAGE) has unveiled a strategic reorganization initiative aimed at prioritizing the commercialization of ZURZUVAE® for postpartum depression while sharpening its focus on pipeline development, including the…
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative therapies for seizure disorders, has shared new data from its Phase 3 RAISE trial on intravenous (IV) ganaxolone for…
Artesunate AMIVAS, the first fully licensed treatment for severe malaria in Europe, is now available for purchase across Europe and the U.K. through Nordic Prime in Denmark. Approved by the…
Helfie AI, a global leader in mobile health technology, has strengthened its Board of Directors with the addition of two healthcare veterans. Antonin (Tony) de Fougerolles, PhD, a distinguished scientist…
Viatris Signs Exclusive Licensing Deal with Lexicon for Sotagliflozin Outside U.S. and Europe PITTSBURGH, Oct. 16, 2024 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS) has reached an exclusive licensing agreement with…
Shimadzu Corporation, Eisai Co., Ltd., Oita University, and the Usuki City Medical Association have demonstrated that blood biomarkers can effectively predict amyloid beta (Aβ) accumulation in the brain, a major…
Shionogi & Co., Ltd. recently presented findings at IDWeek 2024 from the PROVE study, the largest global real-world evidence study on cefiderocol (marketed as Fetroja®/Fetcroja®), a siderophore cephalosporin antibiotic for…
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO), announced its fourth consecutive Platinum Award from The Asset ESG (Environmental, Social, and Governance)…
BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024 San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the…
Alnylam Submits Type II Variation to EMA for Vutrisiran in ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2024—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced the submission of a Type II…
Sanofi and Orano Partner to Develop Next-Generation Radioligand Therapies Paris, October 17, 2024 – Sanofi and Orano Med, a subsidiary of the Orano Group and a leader in targeted alpha…
AstraZeneca Showcases Key Advances in Respiratory Infection Protection at IDWeek 2024 AstraZeneca is set to present significant new findings on the protection against serious respiratory infections caused by respiratory syncytial…